Valeant, Pershing Trying To Hide Behind SEC, Investors Say
Investors behind a class action accusing hedge fund Pershing Square and Valeant Pharmaceuticals of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. have told...To view the full article, register now.
Already a subscriber? Click here to view full article